How to Execute Global Licensing Deals in Biotech Industry
Mar 25 2020
Moderator:
Echo Hindle-Yang, CEO at MSQ
Invited guests:
About Abpro:
Abpro is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. The company is initially focused on novel bi-specific antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. By leveraging our proprietary DiversImmune and MultiMab antibody discovery and engineering platforms, we are developing a pipeline of potentially best-in-class antibodies, both independently and through collaborations with global pharmaceutical and research institutions.